Phase II study of allovectin-7 as an immunotherapeutic agent in patients with stages III and IV melanoma

Trial Profile

Phase II study of allovectin-7 as an immunotherapeutic agent in patients with stages III and IV melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2011

At a glance

  • Drugs Velimogene aliplasmid (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2011 Results presented at 47th Annual Meeting of the American Society of Clinical Oncology (ASCO-2011).
    • 11 Jan 2011 Results from this trial have been published in the journal Immunotherapy, according to a Vical media release.
    • 12 May 2010 Results have been published in Melanoma Research, and Expert Opinion on Biological Therapy, according to a Vical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top